Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage (Q43603825)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage (English)

1 reference

Europe PubMed Central

25 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

25 November 2017

11

1 reference

Europe PubMed Central

25 November 2017

8

object named as

Ray Borrow

1 reference

Europe PubMed Central

25 November 2017

Mariagrazia Pizza

9

object named as

Mariagrazia Pizza

1 reference

Europe PubMed Central

25 November 2017

author name string

Giacomo Frosi

1

1 reference

Europe PubMed Central

25 November 2017

Alessia Biolchi

2

1 reference

Europe PubMed Central

25 November 2017

Morena Lo Sapio

3

1 reference

Europe PubMed Central

25 November 2017

Stefanie Gilchrist

5

1 reference

Europe PubMed Central

25 November 2017

Jay Lucidarme

6

1 reference

Europe PubMed Central

25 November 2017

Jamie Findlow

7

1 reference

Europe PubMed Central

25 November 2017

Marzia Monica Giuliani

10

1 reference

Europe PubMed Central

25 November 2017

language of work or name

0 references

publication date

14 August 2013

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

31

1 reference

Europe PubMed Central

25 November 2017

43

1 reference

Europe PubMed Central

25 November 2017

4968-4974

1 reference

Europe PubMed Central

25 November 2017

Meningococcal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

NadA, a novel vaccine candidate of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Human immunity to the meningococcus. II. Development of natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Diagnostic tests 2: Predictive values

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

The challenge of post-implementation surveillance for novel meningococcal vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.006

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.08.006

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43603825&oldid=2101845274"